𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinson’s Disease

✍ Scribed by Mahyar Etminan, Sudeep Gill, Dr Ali Samii

Book ID
119925420
Publisher
Springer International Publishing AG
Year
2003
Tongue
English
Weight
92 KB
Volume
26
Category
Article
ISSN
0114-5916

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A comparison of sumanirole versus placeb
A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease
✍ Carlos Singer; Janice Lamb; Amanda Ellis; Gary Layton 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.